Yasin Ayyami, Marjan Ghorbani, Masoumeh Dastgir, Reza Malekzadeh, Tohid Mortezazadeh
{"title":"Chitosan-modified manganese oxide-conjugated methotrexate nanoparticles delivering 5-aminolevulinic acid as a dual-modal T1-T2* MRI contrast agent in U87MG cell detection.","authors":"Yasin Ayyami, Marjan Ghorbani, Masoumeh Dastgir, Reza Malekzadeh, Tohid Mortezazadeh","doi":"10.1007/s10334-024-01169-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Glioblastoma multiforme is a highly aggressive form of brain cancer, and early diagnosis plays a pivotal role in improving patient survival rates. In this regard, molecular magnetic resonance imaging has emerged as a promising imaging modality due to its exceptional sensitivity to minute tissue changes and the ability to penetrate deep into the brain. This study aimed to assess the efficacy of a novel contrast agent in detecting gliomas during MRI scans.</p><p><strong>Materials and methods: </strong>The contrast agent utilized modified chitosan coating on manganese oxide nanoparticles. The modification included adding methotrexate and 5-aminolevulinic acid (MnO<sub>2</sub>/CS@5-ALA-MTX) to target cells with overexpressed folate receptors and breaking down excess hydrogen peroxide in tumor tissue, resulting in enhanced signal intensity in T<sub>1</sub>-weighted MR images but diminished signal intensity in T<sub>2</sub>*-weighted MR images.</p><p><strong>Results: </strong>The nanosystem was characterized and evaluated in MR imaging, safety, and ability to target cells both in vivo and in vitro. MTX-free nanoparticles (MnO<sub>2</sub>/CS@5-ALA NPs) had no obvious cytotoxicity on cell lines U87MG and NIH3T3 after 24/48 h at a concentration of up to 160 µgr/mL (cell viability more than 80%). In this system, methotrexate enables tumor targeting and the MnO<sub>2</sub>/5-ALA improves T<sub>1</sub>-T<sub>2</sub><sup>*</sup>-weighted MRI. In addition, MRI scans of mice with M109 carcinoma indicated significant tumor uptake and NP capacity to improve the positive contrast effect.</p><p><strong>Conclusion: </strong>This developed MnO<sub>2</sub>/CS@5-ALA-MTX nanoparticle system may exhibit great potential in the accurate diagnosis of folate receptor over-expressing cancers such as glioblastoma.</p>","PeriodicalId":18067,"journal":{"name":"Magnetic Resonance Materials in Physics, Biology and Medicine","volume":" ","pages":"909-924"},"PeriodicalIF":2.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Magnetic Resonance Materials in Physics, Biology and Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10334-024-01169-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Glioblastoma multiforme is a highly aggressive form of brain cancer, and early diagnosis plays a pivotal role in improving patient survival rates. In this regard, molecular magnetic resonance imaging has emerged as a promising imaging modality due to its exceptional sensitivity to minute tissue changes and the ability to penetrate deep into the brain. This study aimed to assess the efficacy of a novel contrast agent in detecting gliomas during MRI scans.
Materials and methods: The contrast agent utilized modified chitosan coating on manganese oxide nanoparticles. The modification included adding methotrexate and 5-aminolevulinic acid (MnO2/CS@5-ALA-MTX) to target cells with overexpressed folate receptors and breaking down excess hydrogen peroxide in tumor tissue, resulting in enhanced signal intensity in T1-weighted MR images but diminished signal intensity in T2*-weighted MR images.
Results: The nanosystem was characterized and evaluated in MR imaging, safety, and ability to target cells both in vivo and in vitro. MTX-free nanoparticles (MnO2/CS@5-ALA NPs) had no obvious cytotoxicity on cell lines U87MG and NIH3T3 after 24/48 h at a concentration of up to 160 µgr/mL (cell viability more than 80%). In this system, methotrexate enables tumor targeting and the MnO2/5-ALA improves T1-T2*-weighted MRI. In addition, MRI scans of mice with M109 carcinoma indicated significant tumor uptake and NP capacity to improve the positive contrast effect.
Conclusion: This developed MnO2/CS@5-ALA-MTX nanoparticle system may exhibit great potential in the accurate diagnosis of folate receptor over-expressing cancers such as glioblastoma.
期刊介绍:
MAGMA is a multidisciplinary international journal devoted to the publication of articles on all aspects of magnetic resonance techniques and their applications in medicine and biology. MAGMA currently publishes research papers, reviews, letters to the editor, and commentaries, six times a year. The subject areas covered by MAGMA include:
advances in materials, hardware and software in magnetic resonance technology,
new developments and results in research and practical applications of magnetic resonance imaging and spectroscopy related to biology and medicine,
study of animal models and intact cells using magnetic resonance,
reports of clinical trials on humans and clinical validation of magnetic resonance protocols.